NitroMed s BiDil Survival Data Promising As Drug Moves Closer to Becoming PGx | GenomeWeb

Last week at the American Heart Association's annual meeting in Dallas, NitroMed presented data that could strengthen the position of its quasi-personalized antihypertensive drug, BiDil, while the company positions the drug further into larger pharmacogenomics territory.

Approved in June for use in self-identified blacks who have recently had a heart attack, BiDil has survival benefits that are not adversely affected by its blood-pressure lowering effects, NitroMed officers said at the AMA meeting, according to company statements.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.